# Ameluz

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ameluz
Canonical HTML page: https://gethealthbrief.com/entity/ameluz

## Timeline

- **2026-03-19**: Q4 2025 Earnings — Both companies report year-end results showing strong commercial momentum and narrowing losses.
- **2025-11-10**: Major Health Plan Contract — DarioHealth signs a multi-year agreement with a top-five national US health insurer.
- **2025-07-22**: Biofrontera Supply Chain Update — Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.
- **2025-03-15**: DarioHealth MSK Launch — Full integration of musculoskeletal health modules into the core digital platform.

## Recent coverage (2 stories)

### Biofrontera and DarioHealth Q4 Results Signal Shift Toward Commercial Scaling
2026-03-19 17:04:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.
Full story: https://gethealthbrief.com/story/biofrontera-dariohealth-q4-2025-earnings-analysis

### Biofrontera Inc. Achieves Record 2025 Revenue Amid PDT Market Expansion
2026-03-19 14:57:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.
Full story: https://gethealthbrief.com/story/biofrontera-record-2025-financial-results-dermatology

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.